## **Core Concept**
Reslizumab is a monoclonal antibody used in the treatment of severe asthma. It targets the interleukin-5 (IL-5) pathway, which plays a crucial role in the pathogenesis of asthma, particularly in patients with eosinophilic asthma.

## **Why the Correct Answer is Right**
Reslizumab works by binding to IL-5, preventing it from interacting with its receptor on the surface of eosinophils. This leads to a reduction in eosinophil survival, activation, and migration to the lungs, thereby decreasing airway inflammation and improving asthma symptoms. The correct answer, **D. Severe asthma with eosinophilia**, is right because reslizumab is specifically indicated for patients with severe asthma who have an eosinophilic phenotype, which is characterized by elevated levels of eosinophils in the blood or sputum.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because reslizumab is not primarily used for treating chronic obstructive pulmonary disease (COPD).
- **Option B:** This option is incorrect as reslizumab is not used for cystic fibrosis.
- **Option C:** This option is incorrect because while asthma is related, the specificity to "severe asthma with eosinophilia" makes the broader term "asthma" incorrect.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that reslizumab is specifically used for patients with severe asthma and eosinophilia, who have not responded adequately to other asthma medications. This treatment approach is part of personalized or precision medicine, tailoring therapy to the individual patient's disease characteristics.

## **Correct Answer:** D. Severe asthma with eosinophilia.